
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a diagnostics company specializing in tests for various types of cancer, with a strong portfolio of tests for prostate, thyroid, breast, and bladder cancer. With validated tests and strong clinical evidence, the company has the potential to capture market share from larger competitors in the space. Additionally, the company's planned entry into the $15 billion minimal residual disease market with its TrueMRD platform and its strong revenue growth potential support a positive outlook for this stock.
Bears say
Veracyte is a genomic diagnostics company with a focus on cancer testing. Although the company offers tests for various types of cancer, including prostate, thyroid, breast, and bladder cancer, its revenue growth may be unsustainable, with risks such as weaker-than-expected sales and margins. The company's 12-month price target of $48 is based on an EV/sales multiple of 5.5x, which is above its industry peers' multiples. However, there is potential for upside to revenue and earnings estimates due to the company's innovative testing practices.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares